Background: Axillary lymph node clearance (ALNC) improves locoregional control
Introduction

Background
Axillary lymph node clearance (ALNC) in patients with early breast cancer reduces axillary recurrence 1, 2 and provides accurate and useful prognostic information. 3 It is also especially useful when adjuvant therapy will be determined based on pathological results. 4, 5 However, ALNC is invasive and results in postoperative morbidity, 6 and there is ongoing controversy about the impact of axillary treatment itself on breast cancer survival. 2, 7 Consequently, several publications since the 1990's have concluded that ALNC can be omitted from standard treatments for early breast cancer 3, [8] [9] [10] [11] [12] and most recently with the NSABP-B-32 trial for clinically nodenegative breast cancer patients 13 . Developments in early mammographic screening resulting in earlier diagnosis and reduced numbers of involved nodes per patient have also strengthened the idea that ALNC can be omitted, as have studies reporting that even when involved nodes are left in place (without clearance), the risk of axillary recurrence is low. 9, 10, 14, 15 The omission of ALNC has been promoted by randomized controlled trials. The
International Breast Cancer Study Group (IBCSG) 6 and Martelli 11 found similar overall and breast cancer mortality for patients for whom ALNC was not performed.
Sanghani's meta-analysis 2 concludes that performing ALNC does not confer a survival benefit in early clinically node-negative breast cancer, although it is associated with a reduced risk for axillary recurrence.
However, not all reports have agreed with these findings, with doubts being expressed regarding the removal of lymph nodes without deliberate ALNC in the Martelli trial and the potential inadequacy of the statistical power for measuring such small differences in survival rates. 3 Orr's 4 meta-analysis of six trials comparing M A N U S C R I P T
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context, it remains unclear whether the omission of ALNC from the standard treatment of early breast cancer confers a survival advantage, or disadvantage, or neither.
At the time the present study was started, the SLN practice had not yet been introduced into standard clinical practices and ALNC was almost systematically performed. This pragmatic trial was thus designed to evaluate whether survival outcomes after a treatment program involving surgery (with no clearance) + adjuvant treatments for clinically node-negative early breast cancer in postmenopausal women, would be equivalent to survival outcomes after treatment involving surgery + ALNC + adjuvant treatments. Secondary objectives were to examine functional impairments of the two groups and to examine the rates of axillary node events when nodes are left intact, i.e. for patients not receiving ALNC.
Methods
Participants
Eligible patients were post-menopausal women aged 50 and older with early invasive breast cancer (tumor size ≤ 10 mm). Baseline exclusion criteria were: inflammation, palpable axillary nodes (N+), metastasis, prior contralateral invasive cancer or another carcinoma, or limited survival prognosis (<10 years). All patients gave informed, written consent according to the regional ethics committee and legal requirements in France at the time.
Randomization was performed by block, stratified by center and by operation time:
either histological diagnosis was known and randomization was performed after histological analysis; or, randomization was performed intra-operatively and was based on histological extemporaneously-assessed size. They were randomized into two groups: no-Ax that received surgery and adjuvant treatment and Ax (reference treatment) that received surgery, standard ALNC and adjuvant treatment. 
Interventions
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 6
Endpoints
The primary endpoint was OS at five years. OS was defined as time from random assignment to death of any cause. Secondary outcomes were event-free survival (EFS) measured as time from randomization to first event and functional outcomes.
First events were considered as: any recurrence (local, locoregional, axillary or metastatic), contralateral breast cancer, other cancer or death of any cause. We also examined functional impairments and axillary node progressions (associated or not with metastasis). The rate of axillary recurrence was evaluated every six months to ensure that it had not risen over 10%, a condition that would result in an immediate discontinuation of the trial.
Statistical methods
This two-sided equivalence trial was designed to compare OS in the no-Ax group to the Ax group (estimated at 95% based on previous published data). 12, 16 Using a twosided 0.10-level test, 105 events (1 612 patients) were required for 90% power over five years. The equivalence margin was set at 3%, that is, equivalence will be admitted if HR is inferior to 1.6, or if OS in the no-Ax group is not less than 92%. 
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Baseline data
As shown in Table 1 , baseline characteristics of patients on inclusion such as age, initial surgical treatment and tumor size were balanced across groups. Ninety-six percent of patients had a lumpectomy and four percent had a mastectomy.
Histological tumor size was, for the majority (over 65%), between 6-10mm, with the same mean tumor size across groups (7.1 no-Ax vs 7.25mm Ax). For over 70% of patients that underwent ALNC, more than 10 nodes were removed in accordance with recommendations 18 and on average 12 were examined. Under 8 nodes were cleared for 14% of patients. Positive nodes were found for 42 Ax patients (14%) and for 28 (67%) of these, only one node was involved. While these initial inclusion characteristics were balanced, the proportions of patients receiving adjuvant therapies were not balanced as may be expected in a pragmatic trial 17, 19 where adjuvant treatments changed over time and according to standard practices in each center. Almost all no-Ax patients received adjuvant endocrine therapy compared to two thirds of Ax patients and only 6 received adjuvant chemotherapy compared to 26
Ax patients, as chemotherapy was prescribed only in cases of histologically-proven positive lymph nodes. Radiotherapy was balanced across groups.
Survival outcomes
As Figure 2 shows, at five years, OS per protocol in the no-Ax group (94%) was not despite an attenuation of the difference when the non-censored data are considered.
As shown in Table 2 
Recurrence
As seen in Table 2 , no-Ax patients had higher rates of metastatic events, contralateral breast cancer and axillary events, particularly in the first five years after surgery. Ax patients had no axillary events but twice as many breast/parietal events as for no-Ax patients. The combined rate of breast or axillary events was the same for no-Ax patients (12 events) as for Ax patients (12 events).
Histological examination of the lymph nodes dissected during initial clearance showed that the cancer had involved the axillary nodes for 42 (14%) patients receiving clearance. Assuming similar nodal involvement in the no-Ax group, and combining this with the low rate of axillary recurrence observed (6 patients, 2%), this
indicates that leaving involved lymph nodes intact (i.e. not performing ALNC) is only accompanied by clinical consequences (axillary recurrence) for 14% (6/42) of patients with positive nodes.
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Functional impairments
At 31st December 2008, functional evaluations were recorded for 543 patients. Table   3 shows that less than one in ten no-Ax patients experienced any functional impairments whereas one in four Ax patients experienced moderate to severe functional impairments, with the most common impairments being arm paresthesia , lymphedema, upper arm fatigue and reduced shoulder mobility.
Discussion
Survival outcomes
The equivalence of survival outcomes for post menopausal early breast cancer patients treated with or without ALNC was not demonstrated for several reasons.
Firstly, outcomes in our reference group (ALNC) were higher than expected and higher than for our proposed treatment group. Secondly, we did not obtain the number of patients required to conclude equivalence (or the absence of) statistically.
Thirdly, this is a pragmatic trial that despite starting with balanced groups, compares two treatment strategies that differ in more ways than just the inclusion or omission of ALNC (i.e., more no-Ax patients received endocrine therapy).
Yet, with over 600 patients randomized, clear differences in morbidity rates and interesting locoregional recurrence data, we can propose some interpretations to our results. The higher than predicted survival outcomes in the reference treatment group suggest that survival outcomes after ALNC are better than outcomes after treatment particularly for women >50 years. 21 On closer analysis, in the no-Ax group who were in majority treated by tamoxifen we observe two deaths related to pancreatic cancer and one death due to vascular complications attributed to tamoxifen. However, recent contrasting results suggest that one of the few factors impacting on survival for a similar patient group is the (lack of) adjuvant systematic therapy 22 .
In terms of beneficial effects of chemotherapy, although our groups differ slightly in rates of patients receiving chemotherapy, this difference of 20 patients can hardly explain a difference of 10 more deaths in the no-Ax group. In fact, when we use the adjuvant online program 23 to investigate the actual benefit of first generation chemotherapy on OS, we find an absolute benefit of only 2%. As a result, the differences in outcomes we observed cannot be attributed to the different rates of patients receiving chemotherapy.
Advanced age of our patients (median over 60, 18% of 70) must also be considered when interpreting the patient death rates as most deaths were not breast cancerrelated. This concurs with research demonstrating that although death from breast cancer remains substantial for patients 70 and older, death from other causes becomes increasingly important with age.
3,12,24
Recurrence
Recurrence rates are consistent with previous findings showing relatively low recurrence rates overall. While lymph node recurrence was more frequent for no-Ax patients, breast events were more frequent for Ax patients. An interpretation may be that after ALNC, malignant cells can no longer freely circulate beyond this area and M A N U S C R I P T This finding can only partially be explained by a lack of follow up as patients were followed for more than 15 years 14 and overall it appears that positive lymph nodes are not always followed by an evolution, at least at this stage of the disease. 26 It should also be noted that our results demonstrate that there were never more than five positive nodes found, although more than eight nodes were removed in the clearance procedure for a large majority of patients (86.1%). This offers support for 'limited' ALNC, for small tumors, even for positive SLN patients as recently demonstrated in the ACOSOG trial although it did not reach full recruitment 22, 27 .
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Functional impairments
In terms of morbidity, we observed a higher rate of functional impairment for ALNC patients. Incidences were similar to other reported rates of complications. 28, 29 Our overall rate of 9% of patients experiencing functional impairments in the no-Ax group should be understood as the sum of pre-existing conditions, (not measured in our M A N U S C R I P T
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13 series but estimated around 5% in the literature), 28, 29 plus the consequences of the lumpectomy/mastectomy and radiotherapy procedures. The difference between 9% of no-Ax patients and 28% of Ax patients experiencing functional impairments can be understood as the consequences of the ALNC.
Conclusions
Overall, this research presents mixed results, indicating low rates of axillary recurrence even when involved nodes are left intact but, despite early termination of the trial, an indication of more deaths and lower overall and event-free survival when ALNC is not performed. This may partially be explained by the higher rates of locoregional recurrence in the no-Ax group, particularly in the first five years after treatment. We do not believe that these relatively large differences can be attributed to the slight differences in patients receiving chemotherapy or endocrine therapy. 
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